source
- Zealand sells its rights to Takeda’s blood cancer drug for $100M ahead of FDA approval decisionAs the FDA mulls whether to approve Takeda and Protagonist Therapeutics’ rusfertide, Zealand Pharma has sold its own rights to the blood cancer drug in return for $100 million.Fierce Biotech · 6h ago↗ source
- Study finds cancer patients now wait longer for treatment than a decade agoA new analysis of more than 2.7 million cancer cases shows that the interval between diagnosis and the start of therapy has grown over the past ten years. The researchers examined records from a na…
- Definium's LSD pill shows significant anxiety reduction in Phase 3 trial